Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Pre-Salvage ISS and Other Important Outcome Predictors in CD34 Selected Allogeneic Hematopoietic Cell Transplant for Multiple Myeloma

Adam Bryant, MD MSc, Patrick Hilden, MS, Sergio Giralt, MD, Miguel-Angel Perales, MD, Guenther Koehne, MD PhD

Blood (2018) 132 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2018-99-118625

Published: 2018

Journal Articles

Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma

Lizamarie Bachier Rodriguez, MD, Gunjan L. Shah, MD, Andrea Knezevic, MS, Sean M Devlin, PhD, Molly Maloy, MS, Guenther Koehne, MD PhD, David J. Chung, MD PhD, Heather J. Landau, MD, Sergio Giralt, MD

Blood (2018) 132 (Supplement 1): 2156.

https://doi.org/10.1182/blood-2018-99-119537

Published: 2018

Journal Articles

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Michael Scordo, MD, Gunjan L. Shah, MDMS, Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Sean Devlin, PhD, Molly A. Maloy, MS, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Boglarka Gyurkocza, MD, Hugo Castro-Malaspina, MD, Roni Tamari, MD, Miguel Perales, MD, Sergio A. Giralt, MD, Brian C. Shaffer, MD

Blood (2016) 128 (22): 4621.

https://doi.org/10.1182/blood.V128.22.4621.4621

Published: 2016

Journal Articles

Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Gunjan L. Shah, MDMS, Michael Scordo, MD, Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Molly A. Maloy, MS, Jimmy Nieves, RN, Sean Devlin, PhD, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Brian C. Shaffer, MD, Miguel-Angel Perales, MD, Boglarka Gyurkocza, MD, Hugo R. Castro-Malaspina, MD, Sergio A. Giralt, MD, Roni Tamari, MD

Blood (2016) 128 (22): 1236.

https://doi.org/10.1182/blood.V128.22.1236.1236

Published: 2016

Journal Articles

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Aisha N Hasan, MD, Parastoo B Dahi, MD, Sergio Giralt, MD, Guenther Koehne, MD PhD, Nancy A. Kernan, MD, Esperanza B Papadopoulos, MD, Rachel Lehrman, Irene Rodriguez-Sanchez, Richard J. O'Reilly, MD

Blood (2016) 128 (22): 61.

https://doi.org/10.1182/blood.V128.22.61.61

Published: 2016

Journal Articles

Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution

Heather Landau, MD, Jun Fan, Sergio A. Giralt, MD, Jonathan U. Peled, MD PhD, Hani Hassoun, MD, Alexander M. Lesokhin, MD, Nikoletta Lendvai, MD PhD, Neha S Korde, MD, Sham Mailankody, MD, David J. Chung, MD PhD, Guenther Koehne, MD PhD, Eric L. Smith, MD PhD, Elli Papaemmanuil, PhD, Ola Landgren, MD PhD, Christine Iacobuzio-Donahue

Blood (2016) 128 (22): 2090.

https://doi.org/10.1182/blood.V128.22.2090.2090

Published: 2016

Journal Articles

Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients

Carmen Lau, PharmD, Valkal Bhatt, PharmD, Parastoo B. Dahi, MD, Sean Devlin, PhD, Yeon Yoo, BS, Nelly G. Adel, PharmD, BCOP, BCPS, Chris Mazis, Miguel Perales, MD, Sergio A. Giralt, MD, Guenther Koehne, MD PhD, Doris M Ponce, MD, Genovefa A Papanicolaou, MD, Juliet N. Barker, MBBS (Hons)

Blood (2016) 128 (22): 2219.

https://doi.org/10.1182/blood.V128.22.2219.2219

Published: 2016

Journal Articles

An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Michael Scordo, MD, Gunjan Shah, MD M.S., Molly A. Maloy, MS, Sean Devlin, PhD, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Brian C. Shaffer, MD, Boglarka Gyurkocza, MD, Hugo R. Castro-Malaspina, MD, Roni Tamari, MD, Sergio A. Giralt, MD, Miguel Perales, MD

Blood (2016) 128 (22): 2194.

https://doi.org/10.1182/blood.V128.22.2194.2194

Published: 2016

Journal Articles

The Disease Risk Index Predicts Outcomes Including Relapse and Survival in CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome

Christina Cho, MD, Patrick Hilden, MS, Jonathan U. Peled, MD PhD, Scott T. Avecilla, MD PhD, Pere Barba, MD, Juliet N. Barker, MBBS (Hons), Hugo R. Castro-Malaspina, MD, Sergio A. Giralt, MD, Ann A. Jakubowski, MD PhD, Guenther Koehne, MD PhD, Richard C. Meagher, PhD, Molly A. Maloy, MS, Richard J. O'Reilly, MD, Esperanza B. Papadopoulos, MD, Doris M. Ponce, MD, Marcel R. M. van den Brink, MD PhD, James W. Young, MD, Miguel-Angel Perales, MD

Blood (2016) 128 (22): 3498.

https://doi.org/10.1182/blood.V128.22.3498.3498

Published: 2016

Journal Articles

Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines

Susan Prockop, MD, Aisha Hasan, MD, Ekaterina Doubrovina, MD PhD, H.R. Castro-Malaspina, MD, Juliet N. Barker, MBBS(Hons), FRACP, Parastoo B Dahi, MD, Farid Boulad, MD, Nancy A. Kernan, MD, Guenther Koehne, MD PhD, Craig S. Sauter, MD, Szilard Kiss, MD, Mrinali Patel, MD, Stephanie Suser, BA, Richard J O'Reilly, MD

Blood (2015) 126 (23): 3157.

https://doi.org/10.1182/blood.V126.23.3157.3157

Published: 2015

Journal Articles

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients

Blood (2015) 126 (23): 4332.

https://doi.org/10.1182/blood.V126.23.4332.4332

Published: 2015

Journal Articles

Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Satyajit Kosuri, MD, Boglarka Gyurkocza, MD, Sean Devlin, PhD, Molly Maloy, MS, Cristi Ciolino, MPH CCRP, Taylor Borrill, BA, Ann A. Jakubowski, MD PhD, Esperanza B Papadopoulos, MD, H.R. Castro-Malaspina, MD, Guenther Koehne, MD PhD, Miguel-Angel Perales, MD, Sergio Giralt, MD

Blood (2015) 126 (23): 3095.

https://doi.org/10.1182/blood.V126.23.3095.3095

Published: 2015

Journal Articles

Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical CD34+ Selected Peripheral Blood Stem Cells (PBSC) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection and Frequent Pre-Engraftment Syndrome

Blood (2014) 124 (21): 3903.

https://doi.org/10.1182/blood.V124.21.3903.3903

Published: 2014

Journal Articles

Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients

Aisha N. Hasan, MD, Susan E. Prockop, MD, Guenther Koehne, MD PhD, Ekaterina Doubrovina, MD PhD, Richard J. O'Reilly, MD

Blood (2014) 124 (21): 309.

https://doi.org/10.1182/blood.V124.21.309.309

Published: 2014

Journal Articles

Successful Salvage of High-Risk B-Cell Non-Hodgkin and Hodgkin Lymphoma with Double-Unit Cord Blood Transplantation Provides a Platform for Further Optimization

Parastoo B Dahi, MD, Craig S. Sauter, MD, Sean M. Devlin, PhD, Marissa N Lubin, BA, Doris M. Ponce, MD, Sergio Giralt, MD, Guenther Koehne, MD PhD, Miguel-Angel Perales, MD, Andrew D. Zelenetz, MD PhD, Craig H. Moskowitz, MD, Juliet N. Barker, MBBS(Hons), FRACP

Blood (2014) 124 (21): 1258.

https://doi.org/10.1182/blood.V124.21.1258.1258

Published: 2014

Journal Articles

Third Party Donor Derived CMV Specific T Cells for the Treatment of Refractory CMV Viremia and Disease after Hematopoietic Stem Cell Transplant

Susan E. Prockop, MD, Aisha Hasan, MD, Guenther Koehne, MD PhD, Ekaterina Doubrovina, MD PhD, Craig S. Sauter, MD, Juliet N, Barker, MBBS, Karim Baroudy, Farid Boulad, MD, Sergio Giralt, MD, Ramzi Khalaf, Nancy A. Kernan, MD, Esperanza B Papadopoulos, MD, Doris M. Ponce, MD, Andromachi Scaradavou, MD, Stephanie Suser, Gloria Wasilewski, RN, Richard J. O'Reilly, MD

Blood (2014) 124 (21): 184.

https://doi.org/10.1182/blood.V124.21.184.184

Published: 2014

Journal Articles

T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD)

Izaskun Ceberio, MD, Patrick Hilden, MS, Sean M. Devlin, PhD, Molly Maloy, MA, Jenna D Goldberg, MD, Miguel A Perales, MD, Juliet N Barker, MBBS, (Hons), FRACP, Hugo Castro-Malaspina, MD, Guenther Koehne, MD, PhD, Doris M Ponce, MD, Craig S. Sauter, MD, Marcel R.M. van den Brink, MD, PhD, James W. Young, MD, Richard J. O'Reilly, MD, Sergio Giralt, MD, Ann A. Jakubowski, MD, PhD, Esperanza B Papadopoulos, M.D.

Blood (2013) 122 (21): 3387.

https://doi.org/10.1182/blood.V122.21.3387.3387

Published: 2013

Journal Articles

Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk

Chrystal Landry, MD, Dory Londono, Sean M. Devlin, PhD, Alex Lesokhin, MD, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, David J Chung, MD PhD, Guenther Koehne, MD, PhD, Suresh C. Jhanwar, PhD, Sergio A Giralt, MD, Heather Landau, MD

Blood (2013) 122 (21): 1910.

https://doi.org/10.1182/blood.V122.21.1910.1910

Published: 2013

Journal Articles

T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation For Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics Permits Long-Lasting Remissions In The Absence Of Graft-Versus-Host Disease

Guenther Koehne, MD, PhD, Sean M. Devlin, PhD, Heather Landau, MD, Hani Hassoun, MD, Alex Lesokhin, MD, Nikoletta Lendvai, MD PhD, David J Chung, MD PhD, Christina Bravo, MS, Sergio Giralt, MD

Blood (2013) 122 (21): 2115.

https://doi.org/10.1182/blood.V122.21.2115.2115

Published: 2013

Journal Articles

Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma

Luciano J Costa, MD, PhD, Heather Landau, MD, Jagadish K Venkata, PhD, Yubin Kang, MD., Guenther Koehne, MD, PhD, David J Chung, MD PhD, Nikoletta Lendvai, MD PhD, Tricia Bentz, Sergio Giralt, MD

Blood (2013) 122 (21): 3329.

https://doi.org/10.1182/blood.V122.21.3329.3329

Published: 2013

NARROW

Pre-Salvage ISS and Other Important Outcome Predictors in CD34 Selected Allogeneic Hematopoietic Cell Transplant for Multiple Myeloma

Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution

Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients

An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

The Disease Risk Index Predicts Outcomes Including Relapse and Survival in CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome

Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients

Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical CD34+ Selected Peripheral Blood Stem Cells (PBSC) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection and Frequent Pre-Engraftment Syndrome

Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients

Successful Salvage of High-Risk B-Cell Non-Hodgkin and Hodgkin Lymphoma with Double-Unit Cord Blood Transplantation Provides a Platform for Further Optimization

Third Party Donor Derived CMV Specific T Cells for the Treatment of Refractory CMV Viremia and Disease after Hematopoietic Stem Cell Transplant

T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD)

Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk

T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation For Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics Permits Long-Lasting Remissions In The Absence Of Graft-Versus-Host Disease

Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only